Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
J Neuropsychiatry Clin Neurosci ; 36(1): 45-52, 2024.
Article in English | MEDLINE | ID: mdl-37415502

ABSTRACT

OBJECTIVE: Spontaneous confabulation is a symptom in which false memories are conveyed by the patient as true. The purpose of the study was to identify the neuroanatomical substrate of this complex symptom and evaluate the relationship to related symptoms, such as delusions and amnesia. METHODS: Twenty-five lesion locations associated with spontaneous confabulation were identified in a systematic literature search. The network of brain regions functionally connected to each lesion location was identified with a large connectome database (N=1,000) and compared with networks derived from lesions associated with nonspecific (i.e., variable) symptoms (N=135), delusions (N=32), or amnesia (N=53). RESULTS: Lesions associated with spontaneous confabulation occurred in multiple brain locations, but they were all part of a single functionally connected brain network. Specifically, 100% of lesions were connected to the mammillary bodies (familywise error rate [FWE]-corrected p<0.05). This connectivity was specific for lesions associated with confabulation compared with lesions associated with nonspecific symptoms or delusions (FWE-corrected p<0.05). Lesions associated with confabulation were more connected to the orbitofrontal cortex than those associated with amnesia (FWE-corrected p<0.05). CONCLUSIONS: Spontaneous confabulation maps to a common functionally connected brain network that partially overlaps, but is distinct from, networks associated with delusions or amnesia. These findings lend new insight into the neuroanatomical bases of spontaneous confabulation.


Subject(s)
Connectome , Memory Disorders , Humans , Amnesia/diagnostic imaging , Brain/diagnostic imaging , Brain/pathology , Prefrontal Cortex/pathology , Datasets as Topic
2.
J Neuropsychiatry Clin Neurosci ; 29(4): 308-318, 2017.
Article in English | MEDLINE | ID: mdl-28506192

ABSTRACT

Toxic leukoencephalopathy (TL) is a disorder of brain white matter caused by exposure to leukotoxic agents. Magnetic resonance imaging (MRI) can readily identify this syndrome, and, together with diffusion tensor imaging, MRI continues to offer important insights into its nature. Since the first formal description of TL in 2001, many new leukotoxic disorders have been recognized, and the range of leukotoxins has expanded to include more therapeutic drugs, drugs of abuse, and environmental insults. While the understanding of pathophysiology remains incomplete, TL is increasingly common in clinical practice, and the potential long-term cognitive sequelae of toxic white matter injury merit attention.


Subject(s)
Leukoencephalopathies/etiology , Neurotoxicity Syndromes/etiology , Animals , Brain/diagnostic imaging , Brain/drug effects , Brain/physiopathology , Brain/radiation effects , Humans , Leukoencephalopathies/diagnostic imaging , Leukoencephalopathies/prevention & control , Leukoencephalopathies/therapy , Neurotoxicity Syndromes/diagnostic imaging , Neurotoxicity Syndromes/prevention & control , Neurotoxicity Syndromes/therapy , White Matter/diagnostic imaging , White Matter/drug effects , White Matter/physiopathology , White Matter/radiation effects
6.
J Neuropsychiatry Clin Neurosci ; 29(2): 84-85, 2017.
Article in English | MEDLINE | ID: mdl-28264632

Subject(s)
Neurosciences , Politics , Humans
7.
Mil Med ; 2022 Jan 22.
Article in English | MEDLINE | ID: mdl-35064271

ABSTRACT

INTRODUCTION: Cannabis products, including cannabidiol (CBD) and tetrahydrocannabinol (THC), are increasingly easy to procure and use across the United States. The 2018 National Survey on Drug Use and Health (NSDUH) reported a past-month cannabis use rate of 8.6% among adults 26 years of age or older in the U.S. general population. Cannabis use is commonly reported by U.S. Military Veterans with histories of mild traumatic brain injury (mTBI) receiving services at the Marcus Institute for Brain Health (MIBH), a specialty interdisciplinary clinic serving this population. The aims of this study are to describe the frequency and characteristics of cannabis product use among Veterans evaluated at MIBH and to compare the rate of cannabis use in this group to that in the general and Veteran populations reported in the 2018 NSDUH. MATERIALS AND METHODS: Study data were collected as part of MIBH clinical assessments between January 2018 and December 2019, which included the evaluation of the current use of cannabis products. Affirmative cannabis use responses were clarified with inquiries about the frequency of use, method of administration, product ingredients (i.e., THC and/or CBD), and reason(s) for use. RESULTS: Among 163 MIBH patients (92.6% male), 72 (44.2%) endorsed cannabis product use during the month preceding the clinical assessment. Cannabis users were significantly younger than nonusers. The frequency of past-month cannabis use was significantly greater than that reported in the comparably aged NSDUH survey general and Veteran populations (44.2% vs. 8.6% and 44.2% vs. 7.7%, respectively, both P < .00001). Among the 72 MIBH patients reporting cannabis use, 62 (86.1%) reported THC or combination product use, and 10 (13.9%) reported CBD product use. Concurrent medication use, including psychotropic medications use, did not differ significantly between cannabis users and nonusers. CONCLUSIONS: Self-reported cannabis use is significantly higher in the MIBH population than in similarly aged individuals in the general population and significantly more frequent among younger than older members of this cohort. Self-reported reasons for cannabis use in this cohort included mTBI-associated neuropsychiatric symptoms, sleep disturbances, and pain for which standard treatments (both pharmacologic and nonpharmacologic) provided insufficient relief and/or produced treatment-limiting adverse events. However, cannabis use did not provide sufficient improvement in those symptoms to obviate the need for further evaluation and treatment of those problems at MIBH or to replace, in part or in whole, standard medications and other treatments for those problems. Further study of cannabis use, including standardized individual cannabinoid (i.e., THC and CBD) and whole-plant cannabis preparations, in this and similar cohorts is needed to more fully understand the drivers, benefits, risks, and safety of cannabis use in this and in similar Veteran populations, as well as the potential pharmacological and/or nonpharmacological therapeutic alternatives to cannabis use.

10.
J Neuropsychiatry Clin Neurosci ; 23(4): 449-53, 2011.
Article in English | MEDLINE | ID: mdl-22231317

ABSTRACT

The authors used clock-drawing performance to assess cognition and predict inpatient rehabilitation outcomes among persons with traumatic brain injury. Clock-drawing performance, as assessed with the Clock Drawing Interpretation Scale, predicts rehabilitation length of stay as well as Functional Independence Measure scores at the time of neurobehavioral assessment and rehabilitation discharge.


Subject(s)
Brain Injuries/physiopathology , Brain Injuries/rehabilitation , Psychomotor Performance/physiology , Adult , Aged , Aged, 80 and over , Female , Glasgow Coma Scale , Humans , Inpatients , Length of Stay , Male , Middle Aged , Neuropsychological Tests , Treatment Outcome , Young Adult
11.
J Neuropsychiatry Clin Neurosci ; 21(4): 463-6, 2009.
Article in English | MEDLINE | ID: mdl-19996256

ABSTRACT

The presence of paratonia and primitive reflexes ("frontal release signs"), such as glabellar, snout, suck, grasp, and palmomental responses, after traumatic brain injury predicts performance on bedside cognitive assessments, level of functional independence, and duration of acute inpatient rehabilitation.


Subject(s)
Brain Injuries/physiopathology , Brain/physiopathology , Cognition Disorders/physiopathology , Recovery of Function/physiology , Reflex , Adult , Aged , Brain Injuries/complications , Brain Injuries/rehabilitation , Cognition Disorders/etiology , Cognition Disorders/rehabilitation , Female , Humans , Male , Medical Records , Middle Aged , Neuropsychological Tests , Patient Selection , Predictive Value of Tests , Regression Analysis , Retrospective Studies , Severity of Illness Index , Treatment Outcome
12.
J Am Acad Psychiatry Law ; 37(1): 82-91, 2009.
Article in English | MEDLINE | ID: mdl-19297638

ABSTRACT

Both veterans and jail/prison inmates face an increased risk of suicide. The incarcerated veteran sits at the intersection of these two groups, yet little is known about this subpopulation, particularly its risk of suicide. A Pubmed/Medline/PsycINFO search anchored to incarcerated veteran suicide, veteran suicide, suicide in jails/prisons, and veterans incarcerated from 2000 to the present was performed. The currently available literature does not reveal the suicide risk of incarcerated veterans, nor does it enable meaningful estimates. However, striking similarities and overlapping characteristics link the data on veteran suicide, inmate suicide, and incarcerated veterans, suggesting that the veteran in jail or prison faces a level of suicide risk beyond that conferred by either veteran status or incarceration alone. There is a clear need for a better characterization of the incarcerated veteran population and the suicide rate faced by this group. Implications for clinical practice and future research are offered.


Subject(s)
Prisoners/psychology , Suicide/statistics & numerical data , Veterans/psychology , Adult , Brain Injuries/epidemiology , Brain Injuries/psychology , Female , Humans , Male , Prisoners/statistics & numerical data , Risk Factors , Stress Disorders, Post-Traumatic/epidemiology , Stress Disorders, Post-Traumatic/psychology , United States/epidemiology , Veterans/statistics & numerical data , Suicide Prevention
13.
CNS Drugs ; 22(7): 531-45, 2008.
Article in English | MEDLINE | ID: mdl-18547124

ABSTRACT

Pathological laughing and crying (PLC) is characterized by frequent, brief, intense paroxysms of uncontrollable crying and/or laughing due to a neurological disorder. When sufficiently frequent and severe, PLC may interfere with the performance of activities of daily living, interpersonal functioning, or both, and is a source of distress for affected patients and their families. PLC is also often misunderstood by patients and their families, and is under-recognized by the clinicians caring for patients with this disorder. However, this syndrome is easily recognized when understood properly and is highly responsive to treatment with a variety of pharmacological agents. This review aims to facilitate the diagnosis and treatment of patients with PLC, and begins by providing definitions of mood and affect that will help clinicians distinguish between mood disorders, such as major depression and mania, and disorders of affect, such as PLC. In addition, the various terms used to describe this syndrome are reviewed and a recommendation for the use of the term PLC is made. The core clinical features of PLC are also presented and the epidemiology of this syndrome is reviewed. A discussion of the pathophysiology of PLC, including the neuroanatomic and neurochemical bases, is provided. Finally, the evaluation and treatment of patients with PLC is described. Based on the pathophysiology of PLC and on a detailed review of published treatment studies, SSRIs are recommended as first-line pharmacotherapy for this disorder. When SSRIs are ineffective or poorly tolerated, other treatment options, including TCAs, noradrenergic reuptake inhibitors, novel antidepressants, dopaminergic agents and uncompetitive NMDA receptor antagonists may be useful second-line treatments.


Subject(s)
Crying , Laughter , Nervous System Diseases , Neurotransmitter Agents/therapeutic use , Affect , Humans , Nervous System Diseases/epidemiology , Nervous System Diseases/physiopathology , Nervous System Diseases/therapy , Neuroanatomy , Neurochemistry
14.
J Neurol Sci ; 267(1-2): 154-7, 2008 Apr 15.
Article in English | MEDLINE | ID: mdl-17928004

ABSTRACT

BACKGROUND: Morvan's syndrome is characterized by peripheral nervous system hyperexcitibility (myokymia and neuromyotonia), hyperhydrosis, sleep disorder, limb paresthesias, and encephalopathy. Voltage gated potassium channel antibodies (VGKC abs) are frequently present. Reduplicative paramnesia (RP) has not been reported with this disorder. OBJECTIVE: To describe a patient with Morvan's syndrome presenting with RP. DESIGN: Single case study. PATIENT: A 64-year-old man with several years of myokymia and myoclonus with escalating parasomnia and confusion developed the delusion that a replica of his house and its contents existed 40 mi away. RESULTS: Serum VGKC ab titer was elevated. Neuropsychological testing disclosed executive function and memory deficits. Electromyography demonstrated diffuse myokymia. Treatment with intravenous immunoglobulin and prednisone produced improvement of RP and myoclonus, but not myokymia. CONCLUSION: RP may occur in patients with VGKC ab-associated Morvan's syndrome. Both RP and nervous system hyperexcitability may respond to immunotherapy including intravenous immunoglobulin and corticosteroids.


Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Myokymia/complications , Myokymia/psychology , Potassium Channels, Voltage-Gated/immunology , Schizophrenia, Paranoid/genetics , Schizophrenia, Paranoid/immunology , Anti-Inflammatory Agents/therapeutic use , Autoantibodies/blood , Cognition Disorders/drug therapy , Cognition Disorders/genetics , Cognition Disorders/immunology , Electromyography , Humans , Immunotherapy/methods , Isaacs Syndrome/genetics , Isaacs Syndrome/immunology , Isaacs Syndrome/physiopathology , Male , Memory Disorders/drug therapy , Memory Disorders/genetics , Memory Disorders/immunology , Middle Aged , Muscle, Skeletal/immunology , Muscle, Skeletal/physiopathology , Myokymia/physiopathology , Neuropsychological Tests , Peripheral Nerves/immunology , Peripheral Nerves/physiopathology , Prednisone/therapeutic use , Schizophrenia, Paranoid/drug therapy , Syndrome , Treatment Outcome
16.
Neurol India ; 56(1): 77-8, 2008.
Article in English | MEDLINE | ID: mdl-18310845

ABSTRACT

Young adults with stroke frequently do not have any of the traditional risk factors associated with stroke, prompting a search for other mechanical and hypercoagulable causes. The authors report a young man presenting with stroke and subsequently diagnosed with a carotid dissection. Recurrent strokes while on heparin prompted a search for a second etiology and the patient was found to have antiphospholipid antibody syndrome. Although these conditions may be coincidental, we propose that their interaction was significant in this patient's presentation. Other reports of this association will also be reviewed.


Subject(s)
Antiphospholipid Syndrome/complications , Carotid Artery, Internal, Dissection/complications , Phospholipids/immunology , Stroke/complications , Adult , Carotid Artery, Internal, Dissection/immunology , Coronary Angiography/methods , Humans , Magnetic Resonance Imaging/methods , Male , Stroke/immunology
17.
J Am Acad Psychiatry Law ; 36(3): 310-22, 2008.
Article in English | MEDLINE | ID: mdl-18802178

ABSTRACT

Traumatic brain injury (TBI) is a substantial source of mortality and morbidity world wide. Although most such injuries are relatively mild, accurate diagnosis and prognostication after mild TBI are challenging. These problems are complicated further when considered in medicolegal contexts, particularly civil litigation. Cerebral single photon emission computed tomography (SPECT) may contribute to the evaluation and treatment of persons with mild TBI. Cerebral SPECT is relatively sensitive to the metabolic changes produced by TBI. However, such changes are not specific to this condition, and their presence on cerebral SPECT imaging does not confirm a diagnosis of mild TBI. Conversely, the absence of abnormalities on cerebral SPECT imaging does not exclude a diagnosis of mild TBI, although such findings may be of prognostic value. The literature does not demonstrate consistent relationships between SPECT images and neuropsychological testing or neuropsychiatric symptoms. Using the rules of evidence shaped by Daubert v. Merrell Dow Pharmaceuticals, Inc., and its progeny to analyze the suitability of SPECT for forensic purposes, we suggest that expert testimony regarding SPECT findings should be admissible only as evidence to support clinical history, neuropsychological test results, and structural brain imaging findings and not as stand-alone diagnostic data.


Subject(s)
Brain Injuries/diagnostic imaging , Forensic Psychiatry/instrumentation , Forensic Psychiatry/legislation & jurisprudence , Tomography, Emission-Computed, Single-Photon/methods , Evidence-Based Medicine/legislation & jurisprudence , Humans , Reproducibility of Results , Severity of Illness Index , United States
18.
Ann Palliat Med ; 7(3): 339-348, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29307208

ABSTRACT

BACKGROUND: There is growing interest in the application of palliative care principles to improve care for patients and families affected by neurologic diseases. We developed an interdisciplinary outpatient clinic for patients and families affected by neurologic disorders to better address the problems faced by our highest need patients. We have developed and improved this program over the past three years and share several of our most important lessons as well as ongoing challenges and areas where we see our clinic evolving in the future. METHODS: We provide a description of our clinic logistics, including key steps in the initiation of the clinic, and provide descriptions from similar clinics at other institutions to demonstrate some of the variability in this growing field. We also provide results from a formal one-year quality improvement project and a one-year retrospective study of patients attending this clinic. RESULTS: Our clinic has grown steadily since its inception and maintains high satisfaction ratings from patients, caregivers, and referring providers. To maintain standardized and efficient care we have developed materials for patients and referring physicians as well as checklists and other processes used by our interdisciplinary team. Feedback from our quality improvement project helped define optimal visit duration and refine communication among team members and with patients and families. Results from our chart review suggest our clinic influences advance care planning and place of death. Common referral reasons include psychosocial support, complex symptom management, and advance care planning. Current challenges for our clinic include developing a strategy for continued growth, creating a sustainable financial model for interdisciplinary care, integrating our services with disease-specific sections, improving primary palliative care knowledge and skills within our referral base, and building effective alliances with community neurologists, geriatrics, primary care, nursing homes, and hospices. CONCLUSIONS: Specialized outpatient palliative care for neurologic disorders fills several important gaps in care for this patient population, provides important educational opportunities for trainees, and creates opportunities for patient and caregiver-centered research. Educational initiatives are needed to train general neurologists in primary palliative care, to train neurologists in specialist palliative care, and to train palliative medicine specialists in neurology. Research is needed to build an evidence base to identify patient and caregiver needs, support specific interventions, and to build more efficient models of care in both academic and community settings.


Subject(s)
Ambulatory Care Facilities/organization & administration , Ambulatory Care/organization & administration , Nervous System Diseases/therapy , Palliative Care/organization & administration , Ambulatory Care/standards , Ambulatory Care Facilities/standards , Appointments and Schedules , Colorado , Continuity of Patient Care , Humans , Interdisciplinary Communication , Palliative Care/standards , Patient Care Team , Program Development , Quality Improvement , Retrospective Studies
19.
Arch Neurol ; 64(3): 439-41, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17353391

ABSTRACT

OBJECTIVE: To describe 2 patients with rapidly progressive dementia and risk factors for exposure to chronic wasting disease (CWD) in whom extensive testing negated the possible transmission of CWD. Design/ METHODS: We describe the evaluation of 2 young adults with initial exposure histories and clinical presentations that suggested the possibility of CWD transmission to humans. Patients A 52-year-old woman with possible laboratory exposure to CWD and a 25-year-old man who had consumed meat from a CWD endemic area. INTERVENTIONS: Clinical evaluation, neuropathological examination, and genetic testing. RESULTS: Neuropathological and genetic assessment in the 2 patients proved the diagnoses of early-onset Alzheimer disease and a rare genetic prion disease. CONCLUSION: No convincing cases of CWD transmission to humans have been detected in our surveillance program.


Subject(s)
Health Surveys , Wasting Disease, Chronic/epidemiology , Wasting Disease, Chronic/transmission , Adult , Animals , Colorado/epidemiology , Disease Reservoirs , Female , Humans , Male , Middle Aged , Wasting Disease, Chronic/diagnosis , Wasting Disease, Chronic/physiopathology
20.
CNS Spectr ; 12(10): 764-9, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17934381

ABSTRACT

Secondary mania develops in as many as 9% of persons with traumatic brain injuries. The treatment of posttraumatic mania is not well defined, and agents traditionally used for the treatment of idiopathic manic episodes may not be well suited for use among individuals with traumatic brain injuries. Atypical antipsychotics are indicated for the treatment of idiopathic bipolar disorder, and have been used for other purposes among individuals with posttraumatic neuropsychiatric disturbances. This article offers the first description of the treatment of posttraumatic mania using the atypical antipsychotic quetiapine. Beneficial effects of this agent on posttraumatic mania, cognitive impairments, and functional disability in the subacute post-injury period are described. Possible mechanisms of action are discussed and the need for additional investigation of quetiapine for posttraumatic mania is highlighted.


Subject(s)
Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Bipolar Disorder/etiology , Brain Injuries/psychology , Dibenzothiazepines/therapeutic use , Accidents, Traffic , Adult , Brain/diagnostic imaging , Brain Injuries/diagnosis , Humans , Male , Quetiapine Fumarate , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL